Monday, February 28, 2011 8:11:40 AM
of 40870
DEPO
Depomed has added a news release to its Investor Relations website.
Title: Depomed Announces Receipt of a $48 million Milestone Payment for the Approval of GRALISE(TM)
Date(s): 28-Feb-2011 8:00 AM
For a complete listing of our news releases, please click here
Menlo Park, Calif., February 28, 2011 - Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $48 million milestone payment from Abbott Products, Inc., for the U.S. Food and Drug Administration's approval of GRALISE(TM) (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of the rash associated with shingles.
The early bird gets the worm................
But it's the second mouse that gets the cheese...........
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM